U.S., March 1 -- ClinicalTrials.gov registry received information related to the study (NCT06852963) titled 'A Study of Two Doses of VP-001 Administered Intravitreally in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy Previously Treated with VP001' on Feb. 20.
Brief Summary: This is a repeat-dose, open-label, four arm safety and efficacy study of two doses of VP-001 administered intravitreally in participants with confirmed PRPF31 mutation-associated Retinal Dystrophy and previously treated with VP001.
Study Start Date: June 01, 2025
Study Type: INTERVENTIONAL
Condition:
Retinitis Pigmentosa 11
Retinal Degeneration
Retinal Disease
Eye Diseases Hereditary
Retinal Dystrophies
Intervention:
DRUG: VP-001
VP-001...